


**Supplemental Table 1. Total recovered CFU of UTI89 in neutrophil killing assays.**

CFU recovered/well	Control	THP	THP+NaIO4	THP+AUS
Experiment 1	19000	31000	27000	26000
Inoculum: 37000 CFU	29000	30000	28000	26000
	29000	34000	22000	21000
Experiment 2	23607	19800	16470	15400
Inoculum: 25600 CFU	17568	20900	18666	9900
	13176	22000	13725	17600
Experiment 3	12100	20900	19800	9900
Inoculum: 30000 CFU	18700	26400	14300	18700
	17600	28600	16500	14300



**Supplemental Figure 1. THP effect on neutrophil viability and bacterial growth, and the GalNAc portion of the Sda antigen is dispensable for Siglec-9 binding.** (A) Percent cells positive for propidium iodide of neutrophils pretreated with THP for time given, or not (control), and quantified via flow cytometry. (B) Overnight growth of UPEC UTI89 incubated with given concentrations of THP in either LB or RPMI 1640 supplemented with 10% LB. (C) Plate-based binding assay of immobilized THP with human Siglec-9-Fc and visualized with PE anti-human IgG Fc antibody. THP was pretreated with  $\beta$  hexosaminidase from *Canavalia ensiformis* (500 mU/mL,  $\beta$ -Hex) or *Arthrobacter ureafaciens sialidase* (100 mU/mL, AUS), or both for 1 h. An anti-Siglec-9 antibody was used as a positive control. Data represent the means of two independent experiments performed in technical triplicate with results combined,  $n = 2/\text{group}$ .